Current Status of Epirubicin (Farmorubicin) in the Treatment of Solid Tumours

References

• Ganzina F. 4′-epi-doxorubicin, a new analog of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 1983; 10: 1–22
   PubMed Web of Science ®Google Scholar
• Camaggi C M, Strocchi E, Tamassia V, et al. Pharmacokinetic studies of 4′-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases. Cancer Treat Rep 1982; 66: 1819–24
   PubMedGoogle Scholar
• Robert J, Vrignaud P, Nguyen-Ngoc T, et al. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep 1985; 69: 633–40
   Google Scholar
• Eksborg S, Mattson K. Pharmacokinetics of epirubicin in man. Non-influence of alpha interferon. Med Oncol Tumour Pharmacother 1988; 5: 131–3
   Google Scholar
• Eksborg S, Stendahl U, Antila K. Pharmacokinetics of 4′epi-adriamycin after morning and afternoon intravenous administration. Med Oncol Tumour Pharmacother 1989; 6: 195–7
   Google Scholar
• Domellöf L, Andersson M, Eksborg S. Hepatic arterial chemotherapy and embolization with degradable starch microspheres. Cancer chemotherapy: Challenges for the future, K Kimura. Exerpta Med, Tokyo 1989; 11–22
   Google Scholar
• Weenen H, Lankelma J, Penders P GM, et al. Pharmacokinetics of 4′-epi-doxorubicin in man. Invest New Drugs 1983; 1: 59–64
   Google Scholar
• Eksborg S, Stendahl U, Lönnroth U. Comparative pharmacokinetic study of adriamycin and 4′epi-adriamycin after their simultaneous intravenous administration. Eur J Clin Pharm 1986; 30: 629–31
   PubMed Web of Science ®Google Scholar
• Eksborg S, Andersson M, Domellöf L, Lönnroth U. A pharmacokinetic study of adriamycin and 4′epi-adriamycin after simultaneous intra-arterial liver administration. Med Oncol Tumour Pharmacother 1986; 3: 105–10
   PubMedGoogle Scholar
• Eksborg S. Anthracycline pharmacokinetics; Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin). Acta Oncol 1990; 29: 339–42
   PubMed Web of Science ®Google Scholar
• Di Marco A, Zunino F, Silvestrini R, Gambrucci C, Gambretta R A. Interaction of some daunomycin derivatives with deoxyribonucleic acid and their biological activity. Biochem Pharmacol 1971; 20: 1223–8
   Google Scholar
• Nöel G, Peterson C, Trouet A, Tulkens P. Uptake and subcellular localization of daunorubicin and adriamycin in cultured fibroblasts. Eur J Cancer 1978; 14: 363–8
   PubMed Web of Science ®Google Scholar
• Krishan A, Ganapathi R. Laser flow cytometric studies on intracellular fluorescence of anthracyclines. Cancer Res 1980; 40: 3895–900
   PubMed Web of Science ®Google Scholar
• Di Marco A. Epirubicin: Mechanism of action at the cellular level. Advances of anthracycline chemotherapy: Epirubicin, G Bonadonna. Masson Italia Editori, Milano 1984; 41–7
   Google Scholar
• Salmon S E, Liu Rosa M, Casazza A M. Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemother Pharmacol 1981; 6: 103–10
   PubMed Web of Science ®Google Scholar
• Pigram W J, Fuller W, Hamilton L D. Stereochemistry of intercalation: Interaction of daunomycin with DNA. Nature New Biology 1972; 235: 17–9
   PubMedGoogle Scholar
• Arcamone F, Cassinelli G, Penco S, Vicario G P, Vigenvani A. Chemistry of epirubicin, G Bonadonna. Masson Italia Editore, Milano 1984; 3–28
   Google Scholar
• Peterson C, Paul C. Pharmacokinetics of doxorubicin and daunorubicin in the treatment of acute leukemia. Clinical therapeutics. Anthracyclines and cancer therapy, H Hansen. Excerpta Medica, Amsterdam 1982; 7–17
   Google Scholar
• Israel M, Potti P G, Seshadri R. Adriamycin analogues. Rationale, synthesis, and preliminary antitumor evaluation of highly-active DNA-nonbinding N-(trifluoroacetyl) adriamycin-14–0—hemiester derivatives. J Med Chem 1985; 28: 1223–8
   Google Scholar
• Bachur N R, Gordon S L, Gee M V, Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 1979; 76: 954–7
   PubMed Web of Science ®Google Scholar
• Fridovich I. The biology of oxygen radicals. Science 1978; 201: 875–80
   PubMed Web of Science ®Google Scholar
• Tritton T R, Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 1982; 217: 248–9
   PubMed Web of Science ®Google Scholar
• Tokes Z A, Rogers K E, Rembaum A. Synthesis of adriamycin-coupled polyglutaraldehyde microspheres and evaluation of their cytostatic activity. Proc Natl Acad Sci USA 1982; 79: 2026–30
   PubMed Web of Science ®Google Scholar
• Beraldo H, Garnier-Suillerot A, Tosi L, Lavelle F. Iron(III)-adriamycin and iron(III)-daunomycin complexes: Physico-chemical characteristics, interaction with DNA, and antitumor activity. Biochemistry 1985; 24: 284–9
   PubMed Web of Science ®Google Scholar
• Speyer J L, Green M D, Ward C, . A trial of ICRF-187 to selectively protect against chronic adriamycin cardiac toxicity: Rationale and preliminary result of a clinical trial. Organ directed toxicity of anticancer drugs, M P Hacker, J S Lazo, T Tritton, et al. Martinus Nijhoff, The Hague 1988; 17–30
   Google Scholar
• Ross W E. DNA topoisomerases as targets for cancer therapy. Biochem Pharmacol 1985; 34: 4191–5
   PubMed Web of Science ®Google Scholar
• Shen L L, Pernet A G. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: The target of the drugs is DNA. Proc Natl Acad Sci USA 1985; 82: 307–11
   PubMed Web of Science ®Google Scholar
• Tewey K M, Rowe T C, Yang L, Halligan B D, Liu L F. Adriamycin-induced DNA damage mediated by mammalian topoisomerase II. Science 1984; 226: 466–8
   PubMed Web of Science ®Google Scholar
• Kohn K, Ewig R AG, Erickson L C, Zwelling L A. Measurements of strand breaks and cross-links by alkaline elution. DNA repair: A laboratory manual of research techniques, E C Friedberg, P C Hanawalt. Marcel Dekker, New York 1981; 379–401
   Google Scholar
• Ross W E, Zwelling L A, Kohn K W. Relationship between cytotoxicity and DNA strand breakage produced by adriamycin and other intercalating agents. Int J Radiat Oncol Biol Phys 1979; 5: 1221–4
   PubMedGoogle Scholar
• Ross W E, Smith M. Repair of deoxyribonucleic acid lesions caused by adriamycin and ellipticin. Biochem Pharmacol 1982; 31: 1931–5
   PubMedGoogle Scholar
• Young C W, Weenen H. Pharmacology of epirubicin. Advances in anthracycline chemotherapy: Epirubicin, G Bonadonna. Masson Italia Editori, Milano 1984; 51–60
   Google Scholar
• Di Marco A, Casazza A M, Dasdia T, et al. Changes of activity of daunorubicin, Adriamycin and steroisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety. Chem Biol Interactions 1977; 19: 291–302
   Google Scholar
• Goldin A, Venditti J M, Geran R. The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumors: A review. Invest New Drugs 1985; 3: 3–21
   PubMed Web of Science ®Google Scholar
• Johnson R K, Chitnis M P, Embrey W M, Gregory E B. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 1978; 62: 1535–47
   PubMedGoogle Scholar
• Supino R, Prosperi E, Formelli F, Mariani M, Parmiani G. Characterization of a doxorubicin-resistant murine melanoma line: Studies on cross-resistance and its circumvention. Br J Cancer 1986; 54: 33–42
   Google Scholar
• Gerlach J H, Kartner N, Bell D R, Ling V. Multidrug resistance. Cancer Surveys 1986; 5: 25–46
   PubMedGoogle Scholar
• Moscow J A, Cowan K H. Review. Multidrug resistance. J Natl Cancer Inst 1988; 80: 14–20
   PubMed Web of Science ®Google Scholar
• Pastan I, Gottesman M. Multiple-drug resistance in human cancer. New Engl J Med 1987; 316: 1388–93
   PubMed Web of Science ®Google Scholar
• Bradley G, Juranka P F, Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta 1988; 948: 87–128
   PubMed Web of Science ®Google Scholar
• Friche E, Skovsgaard T, Danø K. Multidrug resistance: Drug extrusion and its counteraction by chemosensitizers. Eur J Haemat 1989; 48(Suppl 42)59–67
   Google Scholar
• Danø K, Skovsgaard T, Nissen N L, Friche E, Di Marco A. Mechanism of resistance to anthracyclines and vinca alkaloids. 13th Int Cancer Congr, Part C. Biology of Cancer 1983; 2: 231–46
   Google Scholar
• Danø K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 1973; 323: 466–83
   PubMed Web of Science ®Google Scholar
• Skovsgaard T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer 1978; 38: 1785–91
   Google Scholar
• Skovsgaard T. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res 1978; 38: 4722–7
   PubMedGoogle Scholar
• Beck W T, Cirtain M C, Lefko J L. Energy-dependent reduced drug binding as a mechanism of vinca alkaloid resistance in human leukemic lymphoblasts. Mol Pharmacol 1983; 24: 485–92
   PubMed Web of Science ®Google Scholar
• Inaba M, Nagashima K, Rai Y S, Fukui M, Yanagi Y. Reversal of multidrug resistance by non-antitumor anthracycline analogs. Gann 1984; 75: 1049–52
   Google Scholar
• Inaba M, Nagashima K. Non-antitumor vinca alkaloids reverse multidrug resistance in P388 leukemia cells in vitro. Gann 1986; 77: 197–204
   Google Scholar
• Cornwell M M, Gottesman M M, Pastan I H. Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. Biol Chem 1986; 261: 7921–8
   Google Scholar
• Naito M, Hamada H, Tsuruo T. ATP/Mg2+ dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J Biol Chem 1988; 263: 11887–91
   PubMed Web of Science ®Google Scholar
• Sehested M, Bindslev N, Demant E JF, Skovsgaard T, Buhl Jensen P. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells. Biochem Pharmacol 1990, (In press)
   Google Scholar
• Ferro-Luzzi Ames F G. The basis of multidrug resistance in mammalian cells: Homology with bacterial transport. Cell 1986; 47: 323–4
   Google Scholar
• Kessel D. Circumvention of resistance to anthracyclines by calcium antagonists and other membrane-perturbing agents. Cancer Surveys 1986; 5: 109–27
   PubMedGoogle Scholar
• Skovsgaard T, Danø K, Nissen N I. Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle. Cancer Treat Rev 1984; 11(Suppl A)63–72
   Google Scholar
• Milne M D, Scribner B H, Crawfold M A. Non-ionic diffusion and the extraction of weak acids and bases. Am J Med 1958; 24: 709–29
   PubMed Web of Science ®Google Scholar
• Siegfried J M, Burke T G, Tritton T R. Cellular transport of anthracyclines by passive diffusion. Biochem Pharmacol 1985; 34: 593–8
   PubMed Web of Science ®Google Scholar
• Keizer H G, Joenje H. Increased cytosolic pH in the multi-drug-resistant human lung tumor cells: Effect of Verapamil. J Natl Cancer Inst 1989; 81: 706–9
   PubMedGoogle Scholar
• Minow R A, Benjamin R S, Gottlieb J A. Adriamycin cardio-myopathy—an oveview with determinaton of risk factors. Cancer Chemother Rep 1975; 6: 195–201
   Google Scholar
• Von Hoff D D, Layard M W, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7
   PubMed Web of Science ®Google Scholar
• Praga C, Beretta G, Vigo P L, et al. Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 1979; 63: 827–34
   PubMedGoogle Scholar
• Weiss A J, Metter G E, Fletcher W S, Wilson W L, Grage T R, Raminez G. Studies on Adriamycin using a weekly regimen demonstrating it clinical effectivensss and lack of cardiac toxicity. Cancer Treat Rep 1976; 60: 813–22
   PubMedGoogle Scholar
• Torti F M, Bristow M R, Howes A E, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Ann Intern Med 1983; 99: 745–9
   PubMed Web of Science ®Google Scholar
• Legha S S, Benjamin R S, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–9
   PubMed Web of Science ®Google Scholar
• Goodyear M DE. Do doxorubicin and its enantiomer 4′-epi-doxorubicin have equivalent activity? A meta-analysis of randomised trials comparing two analogues. Proc Am Assoc Cancer Res 1988; 29: 192
   Google Scholar
• Bertazzoli C, Rovero C, Ballerini L, et al. Experimental systemic toxicology of 4-epirubicin, a new less cardiotoxic anthracycline antitumor agent. Toxicol Appl Pharmacol 1985; 79: 412–22
   PubMed Web of Science ®Google Scholar
• Alexander J, Dainiak N, Berger H J, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979; 300: 278–83
   PubMed Web of Science ®Google Scholar
• Ritchie J L, Singer J W, Thorning D, Sorensen S G, Hamilton G W. Anthracycline cardiotoxicity. Clinical and pathological outcome assessed by radionuclide ejection fraction. Cancer 1980; 46: 1109–16
   PubMed Web of Science ®Google Scholar
• Gottdiener J S, Mathisen D J, Borer J S, et al. Doxorubicin cardiotoxicity: Assessment of late left ventricular dysfunction by the radionuclide cineanogigraphy. Ann Intern Med 1981; 94: 430–5
   PubMed Web of Science ®Google Scholar
• Torti F M, Bristow M M, Lum B L, et al. Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy. Cancer Res 1986; 46: 3722–7
   PubMed Web of Science ®Google Scholar
• Cersosimo R J, Hong W K. Epirubicin: A review of the pharmacology, clinical activity and adverse effects of an adriamycin analogue. J Clin Oncol 1986; 4: 425–39
   PubMed Web of Science ®Google Scholar
• Zulian G B. Acute toxicity of epirubicin. J Clin Oncol 1986; 4: 1867–8
   PubMed Web of Science ®Google Scholar
• Jain K, Casper E S, Geller N L, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985; 3: 818–26
   PubMed Web of Science ®Google Scholar
• Brambilla C, Rossi A, Bonfante V, et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 1986; 70: 261–6
   PubMedGoogle Scholar
• Rosso R, Teresa M, Campora E, et al. Comparative evaluation of doxorubicin vs 4′-epi-doxorubicin cardiotoxicity by radio-nuclide angiography. Proc ECCO-3. Stockholm 1985; 75
   Google Scholar
• Bezwoda W R. Treatment of advanced ovarian cancer: A randomised trial comparing adriamycin or 4′-epi-adriamycin in combination with cisplatin and cyclophosphamide. Med Pediatr Oncol 1986; 14: 26–9
   PubMedGoogle Scholar
• Rivarola E G, Cuneo N, Orsini W, et al. Adriamycin vs epirubicin combination (FAC vs FEC) for advanced breast cancer. Comparison of clinical activity and subclinical cardiotoxicity. Proc Am Soc Clin Oncol 1987; 6: 52
   Google Scholar
• Italian Multicenter Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide vs fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial. J Clin Oncol 1988; 6: 976–82
   PubMedGoogle Scholar
• The French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 1988; 4: 679–88
   Google Scholar
• Humblet Y, Doyen C, Michel C, et al. A randomized phase III study in advanced breast cancer. Cyclophosphamide and vindesine in association with either adriamycin or epirubicin: An interim analysis. Proc Am Soc Clin Oncol 1988; 7: 27
   Google Scholar
• Lopez M, Papaldo P, Lauro L D, Vici P, Carpano S, Conti E MS. 5-fluorouracil, adriamycin, cyclophosphamide (FAC) vs 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. Oncology 1989; 46: 1–5
   PubMed Web of Science ®Google Scholar
• Vorobiof D A, Iturralde M, Falkson G. Assessment of ventricular function by radionuclide angiography in patients receiving 4′-epidoxorubicin and mitoxantrone. Cancer Chemother Pharmacol 1985; 15: 253–7
   Google Scholar
• Rasmussen D, Jensen J, Skovsgaard T, et al. Epirubicin versus epirubicin and vindesine in advanced breast cancer. Proc Am Soc Clin Oncol 1987; 6: 67
   Google Scholar
• Shepherd F A, Feld R, Blackstein M, Gupta S, Cook D J, Lassus M. Administration of high dose bolus epirubicin is not associated with increased cardiotoxicity. Proc Am Soc Clin Oncol 1989; 8: 335
   Google Scholar
• Nagel G A, Marschner N, Rauschning W. Phase II study of high-dose epirubicin/cyclophosphamide in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1989; 8: 36
   Google Scholar
• Hunter J. Observations on certain parts of the animal oeconomy. Bibliotheca Osteriana, London 1786
   Google Scholar
• Huggins C, Hodges C V. Studies on prostatic cancer. I. The effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–7
   Google Scholar
• Schmidt J D. Endocrine therapy for prostatic cancer. Clin Oncol 1983; 2: 357–70
   Google Scholar
• Waxman J. Gonadotrophin releasing hormone analogues for prostatic cancer: An overview. Semin Oncol 1988; 15: 366–70
   Google Scholar
• Mickey D D, Stone K R, Wunderli H, Mickey G H, Vollmer R T, Paulson D F. Heterotransplantation of a human prostatic adenocarcinoma cell line into nude mice. Cancer Res 1977; 37: 4049–58
   PubMed Web of Science ®Google Scholar
• Raghavan D. Non-hormone chemotherapy for prostate cancer: Principles of treatment and application to the testing of new drugs. Semin Oncol 1988; 15: 371–89
   Google Scholar
• Eisenberger M A, Simon R, O'Dwyer P J, Wittes R E, Friedman M A. A reevaluation of non-hormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985; 3: 827–41
   PubMed Web of Science ®Google Scholar
• Eisenberger M A. Chemotherapy for prostate carcinoma. NCI Monogr 1988; 7: 151–63
   Google Scholar
• Tannock I F. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate. J Clin Oncol 1985; 3: 1013–21
   PubMed Web of Science ®Google Scholar
• Pavone-Macaluso M, Lund F, Mulder J H, Smith P H, De Pauw M, Sylvester R, EORTC Urological Group. EORTC protocols in prostatic cancer. An interim report. Scand J Urol Nephrol 1980, Suppl 55: 163–8
   Google Scholar
• Scher H, Yagoda A, Watson R C, Serber M, Whitmore W. Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. J Urol 1984; 131: 1099–102
   PubMed Web of Science ®Google Scholar
• Eagan R T, Hahn R G, Myers R P. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer. Cancer Treat Rep 1976; 60: 115–7
   PubMedGoogle Scholar
• DeWys W D, Begg C B, Brodovsky H, Creech R, Khandekar J. A comparative trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: Prognostic factors and response. Prostate 1983; 14: 1–11
   Google Scholar
• Torti F M, Shortliffe L D, Carter S K, et al. A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer 1985; 56: 2580–6
   PubMed Web of Science ®Google Scholar
• O'Bryan R M, Baker L H, Gottlieb J E, et al. Dose response evaluation of Adriamycin in human neoplasia. Cancer 1977; 39: 1940–8
   PubMed Web of Science ®Google Scholar
• Chlebowski R T, Paroly W S, Pugh R P, et al. Adriamycin given as a weekly schedule without loading course: Clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 1980; 64: 47–51
   PubMedGoogle Scholar
• Torti F M, Aston D, Lum B L, et al. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1983; 1: 477–82
   PubMed Web of Science ®Google Scholar
• Robinson M RG, Chandrysekran S, Newling D WW, Richards B, Smith P H. Low-dose doxorubicin in the management of advanced carcinoma of the prostate. Br J Urol 1983; 55: 747–8
   PubMedGoogle Scholar
• Fosså S D, Urnes T, Kaalhus O. Weekly low-dose adriamycin in hormone-resistant metastatic cancer of the prostate. Scand J Urol Nephrol 1987; 21: 13–6
   PubMed Web of Science ®Google Scholar
• Bonfante V, Bonadonna G, Villani F, Di Fronzo G, Martini A, Casazza A M. Preliminary phase I study of 4′epi-adriamycin. Cancer Treat Rep 1979; 63: 915–8
   PubMedGoogle Scholar
• Schauer P K, Wittes R E, Gralla R J, Casper E S, Young C W. A phase I trial of 4′-epi-doxorubicin. Cancer Clin Trials 1981; 4: 433–7
   PubMedGoogle Scholar
• Jones W G, Fosså S D, Bono A V, Klijn J GM, De Pauw M, Sylvester R. European organization for research and treatment of cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. Cancer Treat Rep 1987; 71: 1317–8
   PubMedGoogle Scholar
• Citrin D L, Hogan T F, Davis T E. Chemohormonal therapy in metastatic prostate cancer. Cancer 1983; 52: 410–4
   PubMed Web of Science ®Google Scholar
• Kontturi M, Sotarauta M, Tammela T, Lukkarinen O, Romppainen M L, Gröhn P. Sequentially alternating hormone chemotherapy with high-dose medroxyprogesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostate cancer. Eur Urol 1988; 15: 43–7
   Google Scholar
• Aabo K. Prostate cancer: Evaluation of response to treatment, response criteria, and the need for standarization of the reporting of results. Eur J Cancer Clin Oncol 1987; 23: 231–6
   Google Scholar
• Emrich L J, Priore R L, Murphy G P, Brady M F. and the investigators of the National Prostatic Cancer Project. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 1985; 45: 5173–9
   Google Scholar
• Donovan K, Dandon-Fisher R W, Redman S. Measuring quality of life in cancer patients. J Clin Oncol 1989; 7: 959–68
   PubMed Web of Science ®Google Scholar
• Soloway M S. Introduction and overview of intravesical therapy for superficial bladder cancer. Urology 1988, Suppl 31: 3
   Google Scholar
• Herr H W, Laudone V P. Intravesical therapy for superficial bladder cancer. Cancer: Prince Pract Oncol Updates 1988; 2: 1–10
   Google Scholar
• Groos E, Walker L, Masters J RW. Intravesical chemotherapy. Studies on the relationship between pH and cytotoxicity. Cancer 1986; 58: 1199–203
   PubMedGoogle Scholar
• Hellsten S, Axelsson B, Eksborg S, Lindqvist C. Experimental studies of 4-epidoxorubicin and doxorubicin after intravesical instillation. Scand J Urol Nephrol 1987; 21(Suppl 105)1
   Google Scholar
• Mross K, Maessen P, Van der Vijgh W JF, Bogdanowicz J F, Kurth K H, Pinedo H M. Absorption of epi-doxorubicin after intravesical administration in patients with in situ transitional cell carcinoma of the bladder. Eur J Cancer Clin Oncol 1987; 23: 505–8
   Google Scholar
• Calais da Silva F, Denis L, Bono A, Bollack C, Bouffious C. Intravesical chemoresection with 4′-epi-doxorubicin in patients with superficial bladder tumours. Eur Urol 1988; 14: 207–9
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Tsushima T, Ozaki Y, et al. Intravesical chemotherapy with 4′-epi-adriamycin in patients with superficial bladder tumors. Cancer Chemother Pharmacol 1986; 16: 176–7
   PubMed Web of Science ®Google Scholar
• Lukkarinen O, Hellström P, Kontturi M, Tammela T. Prevention of recurrence of superficial urinary bladder cancer by local administration of Farmorubicin. Second Nordic Conference on Chemotherapy in Urological Tumours. Soria Moria, Oslo 1988
   Google Scholar
• Sternberg C N, Yagoda A, Scher H I, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403–7
   PubMed Web of Science ®Google Scholar
• Fosså S D, Splinter T, Roozendall K J, et al. A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer. EORTC-GU Group Protocol 30867. Eur J Cancer Clin Oncol 1989; 25: 389–90
   Google Scholar
• Jones W G, Sokal M, Newling D WW. A phase II study of epirubicin in advanced transitional cell bladder cancer—a preliminary (toxicity) report. Pharmorubicin Update 88. Symposium, London, April, 1988
   Google Scholar
• Roberts J T, Hall R R, McNeill F, Marsh M. EPIC-M (epirubicin, cisplatinum and methotrexate) in locally advanced and metastatic carcinoma of the urinary tract. Pharmorubicin Update 88. Symposium, London, April, 1988
   Google Scholar
• Kriegmair M, Pensel J, Muschter R, Hofstetter A. MVEC-chemotherapy of advanced transitional cell carcinoma. Pharmorubicin Update 88. Symposium, London, April, 1988
   Google Scholar
• Rassweiler J, Rüther U, Bäuerle K, Bub P, Jipp P, Eisenberger F. Polychemotherapie nach dem M-VEC Schema (methotrexate, vinblastine, epirubicin, cisplatin) beim fortgeschrittenen Harnblasenkarzinom—Effektivität und Toxizität. Urologe 1989; 28: 25–30
   Google Scholar
• Scher H, Herr H, Sternberg C, et al. Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. Br J Urol 1989; 64: 250–6
   PubMedGoogle Scholar
• Bunn P A, Jr. Lung cancer: The current approach to diagnosis, staging and treatment. Sieber and McIntyre Inc, Chicago 1983; 1–46
   Google Scholar
• Bork E, Hansen M, Dombernowsky P, Pedersen A G, Hansen H H. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients. J Clin Oncol 1986; 4: 524–7
   Google Scholar
• Minna J D, Higgins G A, Glatstein E J. Cancer of the lung. Cancer: Principles and practice of oncology, ed. 2, V T DeVito, Jr, S Hellman, S A Rosenberg. JB Lippincott Co, Philadelphia 1985; 507–97
   Google Scholar
• Sørensen J B, Clerici M, Hansen H H. Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review. Cancer Chemother Pharmacol 1988; 21: 89–102
   PubMed Web of Science ®Google Scholar
• Sørensen J B, Østerlind K, Hansen H H. Vinca alkaloids in the treatment of non-small cell lung cancer. Cancer Treat Rev 1987; 14: 29–51
   Google Scholar
• Sørensen J B, Hansen H H. Combination chemotherapy for advanced adenocarcinoma of the lung. A review. Cancer Chemother Pharmacol 1988; 21: 103–16
   Google Scholar
• Evans B D, Macanlay V, Smith I E. Weekly low-dose epirubicin. A phase II study in breast cancer and small cell lung cancer. Clin Trials J 1987; 24(Suppl 1)107–10
   Google Scholar
• Gatzemeier U, Heckmayr M. Mono-chemotherapy of small-cell-lung-cancer with a weekly regimen of 4-epirubicin in elderly patients. Proc ECCO-4. Madrid 1987; 6
   Google Scholar
• Johnson J R, Morgan D A. A Phase II evaluation of 4′-epi-doxorubicin (epirubicin) in small cell lung cancer. Br J Cancer 1987; 56: 871
   Google Scholar
• Feld R, Blackstein M, Wierzbicki R, et al. High dose epirubicin in patients with untreated extensive non-small cell and small cell lung cancer. The evolving role of anthracyclines. Excerpta Medica 1988; 87: 3–5
   Google Scholar
• Kolaric K, Eckhardt S, Kaplan E, Intini C, Schoket Z, Kerpel-Fronins S. Phase II study of high dose 4′epi-doxorubicin (4-EPI DX) in previously untreated patients with extensive disease small cell lung cancer (SCLC). Proc 6th NCI-EORTC Symposium, Amsterdam, 1989, 321
   Google Scholar
• Banham S W, Henderson A F, Milroy R, Monie R D. Phase II study of high dose epirubicin in poor prognosis small cell lung cancer (SCLC). Proc ASCO 1988; 7: 217
   Google Scholar
• Santoro A, Bidoli P, Bedini V, Cataldo I, Valagussa P, Bonadonna G. Induction chemotherapy with anthracyclines and ifosfamide in the treatment of small cell lung cancer. Proc ECCO-4. Madrid 1987; 8
   Google Scholar
• Drings P, Bulzebruck H, Hruska D, Manke H G, Schuler G. EPICO für die Behandling des kleinzelligen Bronchialkarzinomas. Onkologie 1986; 9: 14–20
   Google Scholar
• Fritze D, Harjung H, Katz R, Kober B. Ergebnisse der palliativen Chemotherapie bei fortgeschrittenem kleinzelligem Brochialkarzinom. Dtsch Med Wschr 1988; 43: 1663–8
   Google Scholar
• Lelli G, Casadio M, Giordani S, et al. 4′-epidoxorubicin plus cisplatin as first-line therapy in the treatment of small cell bronchogenic carcinoma. Chemioterapia 1987; 6: 134–6
   Google Scholar
• Gilby H, Newmann H, Pickering J. Epirubicin and etoposide in small cell lung cancer (SCLC): Acceptable toxicity. Proc ASCO 1989; 8: 241
   Google Scholar
• Samandas E, Skarlos D, Barlas K, et al. Combination chemotherapy of small cell lung cancer (SCLC) with epirubicin (EP) cyclophosphamide (C), etoposide (VP-16) and prophylactic cranial irradiation (PCI) (Prospective study). Proc 5th World Conf on Lung Cancer. 1988, 48, 6.1
   Google Scholar
• Agosti E, De Rosa C, Bosio G, Morandi R. Cisplatino-etoposide alternati a ciclofosfamide-epirubicin-vincristina nel tratamento del carcinoma polmonare a piccole cellule. Minerva Pneumol 1988; 27: 171–3
   Google Scholar
• Eich F, Sybrecht G W. Efficacy of epirubicin, cyclophosphamide, and vincristine alternating with cisplatin and etoposide in the treatment of patients with small cell cancer of the lung. J Cancer Res Clin Oncol 1988; 114(Suppl)183
   Google Scholar
• Stahlknecht T, Gatzemeier U, Heckmayr M, Neuhauss R. Chemotherapy of SCLC with 4-epirubicin/ifosfamide and vindesine. J Cancer Res Clin Oncol 1988; 114(Suppl)182
   Google Scholar
• Nikkanen T AV, Jakobsson M, Järvinen M, et al. Doxorubicin and 4′-epidoxorubicin in combination chemotherapy of extensive small cell lung cancer. Acta Oncol 1988; 27: 75–6
   Web of Science ®Google Scholar
• Smith A P, Andersen E G, Chappell A G. Epirubicin and small cell lung cancer. A pilot study of the efficacy and toxicity of epirubicin and doxorubicin (Adriamycin). Clin Trials J 1987; 24(Suppl 1)195–202
   Google Scholar
• Kalman L A, Kris M G, Gralla R J, et al. Phase II trial of 4′epi-doxorubicin in patients with non-small cell lung cancer. Cancer Treat Rep 1983; 67: 591–2
   Google Scholar
• Wertheim MKris S. G, Gralla R J, et al. Phase II studies on three new anthracyclines in non-small cell lung cancer (NSCLC). Proc ASCO 1985; 4: 190
   Google Scholar
• Meyers F J, Cardiff R D, Quadro R, et al. Epirubicin in non-oat cell lung cancer-response rates and the importance of immunopathology: A Northern California Oncology Group Study. Cancer Treat Rep 1986; 70: 805–6
   Google Scholar
• Schütte J, Niederle N, Grunenberg B, Krischke W, Seeber S, Schmidt C G. 4′epi-doxorubicin—A clinical phase-II trial in solid tumors. J Cancer Res Clin Oncol 1984; 107: 38–41
   Google Scholar
• Martoni A, Giovannini M, Tomasi L, et al. A phase-II clinical trial of 4′-epi-doxorubicin in advanced solid tumors. Cancer Chemother Pharmacol 1984; 12: 179–82
   Google Scholar
• Mattson K. Phase II trial of epirubicin in non-small cell lung cancer. Preliminary results of a multicenter study. Proc Farmorubicin Symposium, Helsinki, 1986
   Google Scholar
• Joss R A, Hansen H H, Hansen M, Renards J, Rozencweig M. Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung. Eur J Cancer Clin Oncol 1984; 20: 495–9
   Google Scholar
• Feld R, Blackstein M, Wierzbicki R, et al. High dose epirubicin in patients with untreated extensive non-small cell and small cell lung cancer. The evolving role of anthracyclines. Exerpta Medica 1988; 87: 3–5
   Google Scholar
• Holdener E E, Jungi W J, Fiebig H H, et al. Phase I study of high-dose epirubicin in non small cell lung cancer (NSCLC). Proc ASCO 1988; 7: 208
   Google Scholar
• O'Bryan R M, Luce J K, Talley R W, et al. Phase II evaluation of adriamycin in human neoplasia. Cancer 1973; 32: 1–3
   PubMed Web of Science ®Google Scholar
• Knight E W, Lagakos S, Stolbach L, et al. Adriamycin in the treatment of far-advanced lung cancer. Cancer Treat Rep 1976; 60: 939–41
   Google Scholar
• Fujita J, Saijo N, Eguchi K, et al. Preliminary phase II study of Adriamycin (ADM) in patients with non-small cell lung cancer (NSCLC). Jpn J Clin Oncol 1985; 15: 365–8
   Google Scholar
• Cortes E P, Takita H, Holland J F. Adriamycin in advanced bronchogenic carcinoma. Cancer 1974; 34: 518–21
   Google Scholar
• Lelli G, Farris A, Casadio M, et al. 4′-epidoxorubicin and cis-diamminedichloroplatinum in advanced non-small cell bronchogenic carcinoma. A phase II study. J Exp Clin Cancer Res 1986; 5: 185–90
   Google Scholar
• Ries F, Dicato M, Lobelle J P. A phase II trial with high dose epirubicin (E) and cisplatin (P) in stage III or IV non small cell lung cancer. Proc ASCO 1989; 8: 233
   Google Scholar
• Contu A, Pari P, Poddighe M, et al. Non small cell lung cancer treated with VP-16, epi-adriamycin and cisplatin. Proc ECCO-4. Madrid 1987; 24
   Google Scholar
• Tucci E, Algeri R, Trusso M, et al. Cisplatinum, epirubicin and VP-16 (PEV) in advanced adenocarcinoma and squamous cell carcinoma of the lung. A pilot study. Proc ASCO-4. 1987; 27
   Google Scholar
• Wils J, Utama I, Smeets J. Chemotherapy consisting of epirubicin, cisplatin, and etoposide followed by irradiation in stage III non-small cell lung cancer and chemotherapy alone in stage IV non-small lung cancer. Oncology 1988; 45: 413–6
   Google Scholar
• Altavilla G, Adamo V, Alafaci E, et al. Treatment on non-small cell lung carcinoma (NSCLC) with VP16 epirubicin and procarbazine. Proc Eur Soc Med Oncol 1988; C90
   Google Scholar
• Demicheli R, Bonciarelli G, Jirillo A, Lonardi F, Balli M. Bleomycin, vincristine, mitomycin and cisplatin alternated with cyclophosphamide, 4-epidoxorubicin and procarbazine in advanced non-small cell lung cancer. Tumori 1988; 74: 563–6
   Google Scholar
• Sørensen J B. Etoposide and teniposide in non-small cell lung cancer, Unpublished data
   Google Scholar
• Cartei G, Bian R, Cendron R, et al. Evaluation of synergy with cis-platinum (DDP) in non small cell lung cancer (NSCLC): Interim report from a multicentric study. Proc ASCO 1988; 198
   Google Scholar
• Pannuti F, Lelli G, Casadio M, Giordani S, Ferrari P. High doses of cisplatin (C) plus 4′-epidoxorubicin (E) vs low doses of C + F or C + etoposide (V) in the treatment of non small cell lung cancer. Proc 4th World Conf in Lung Cancer. 1985, 12
   Google Scholar
• Cellerino R, Tummarello D, Porfiri E, et al. Non small cell lung cancer (NSCLC): Results of a prospective randomized study comparing treatment (CEP/MEC') vs supportive care. Eur J Cancer Clin Oncol 1988; 24: 1839–43
   Google Scholar
• Rosell R, Abad-Esteve A, Morera J, et al. A randomized study comparing platinum, doxorubicin, and VP-16 with platinum, 4′epidoxorubicin, and VP-16 in patients with non-small cell lung cancer. Am J Clin Oncol 1987; 10: 245–8
   PubMed Web of Science ®Google Scholar
• Tropé C. A phase II study of 4′epi-doxorubicin in advanced ovarian carcinoma. Proc ASCO 1982; 1: C–-472
   Google Scholar
• Tropé C, Christiansson T, Johnsson A, Bergryd M. A phase II study of 4′epi-doxorubicin in advanced ovarian carcinoma. Proc 13th Intern Congr Chemotherapy 1983; 215: 36–8
   Google Scholar
• Tropé C, Kjørstad K E. Phase II studies of 4′epi-doxorubicin as a single drug and in combination with cisplatinum in advanced ovarian carcinoma. Tumori Delle Gonadi, T Batelli, P Manocci, R Mattioli, G Bonadonna, G Mariuzzi, C Romanini. Ancona-Jesi. 1987; 389–95
   Google Scholar
• Young R C, Knopp R C, Perez C A. Cancer of the ovary. Cancer principles and practice of oncology, V T De Vita, Jr, S Hellmann, S A Rosenberg. JB Lippincott Co, Philadelphia 1982; 884–913
   Google Scholar
• Simonsen E, Bengtsson C, Hegberg T. A phase II-study of the effect of 4′epi-doxorubicin, administered in high-dose 150 mg in 24 hours intravenous infusion in advanced carcinoma. Proc ECCO-4. Madrid 1987; 226
   Google Scholar
• Martoni A, Tomasi G, Farabegoli F, Fruet F, Panutti F. 4′epi-doxorubicin in combination with cis-platin in advanced ovarian cancer. Cancer Treat Rep 1984; 68: 1391–3
   Google Scholar
• Christman D. Epirubicin in der Kombinations-Chemotherapie des metastasierten Mammakarzinomas (VEC) und des fortgeschrittenen Ovarialkarzinoms (PEC). Onkologie 1986; 9(Suppl 1)11–2
   Google Scholar
• Presti M, Carlino M, Vassena G, Anaboni F, Holis G. Rescue treatment with platinum (P) and epirubicin (E) in relapsing ovarian cancer. Proc ESMO 1988; C26
   Google Scholar
• Ozols R F, Young R C. Chemotherapy of ovarian cancer. Semin Oncol 1984; 11: 251–63
   PubMed Web of Science ®Google Scholar
• Tobias J S, Griffiths C T. Management of ovarian carcinoma: Current concept and future prospects. New Eng J Med 1976; 294: 818–23
   PubMed Web of Science ®Google Scholar
• Eckhardt S, Szanto T, Cerar O, et al. Activity of epirubicin in combination chemotherapy of advanced ovarian cancer. Oncology 1987; 44: 1–4
   Google Scholar
• Mechl Z, Kopecny J, Ptachova B. CEP combination chemotherapy in the treatment of advanced ovarian cancer. Proc ECCO-3. Stockholm 1985; 116
   Google Scholar
• Landoni F, Redaelli L, Bonazzi C, Algeri R, Chiari S, Regallo M. A phase II trial of sequential induction chemotherapy with epiadriamycin (E), cyclophosphamide (C) and cisplatinum (P) in advanced ovarian cancer patients (OCP). Proc ECCO 4. Madrid 1987; 226
   Google Scholar
• Lorusso V, Maiello E, De Leonardis E, Traversa A, Marzullo F, de Lena M. PAC/PEC combination in stage III-IV ovarian carcinoma. Proc 14th Intern Congr Cancer. 1986; 1006
   Google Scholar
• Hernádi Z, Juhasz B, Pokar A, Lampe L G. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4′epi-adriamycin in the treatment of advanced ovarian cancer. Int J Gynecol Obstet 1988; 27: 199–204
   PubMed Web of Science ®Google Scholar
• Conte P F, Bruzzone S, Chiara S, et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 1986; 4: 965–71
   PubMed Web of Science ®Google Scholar
• Bertelsen K, Jakobsen A, Anderson J E, et al. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 1987; 28: 161–9
   PubMed Web of Science ®Google Scholar
• Gruppo Interregionale Cooperativo Oncologico Ginecologia. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 1987; 2: 353–9
   Google Scholar
• Omura G A, Bundy B N, Berek J S, Curry S, Delgado G, Martel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A gynecologic oncology group study. J Clin Oncol 1989; 7: 457–65
   PubMed Web of Science ®Google Scholar
• Omura G, Blessing J A, Ehrlich C E, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer 1986; 57: 1725–30
   PubMed Web of Science ®Google Scholar
• Bruckner H W, Cohen C J, Goldberg J, Kabakow B, Wallach R, Holland J F. Ovarian cancer: Comparison of Adriamycin and cisplatin ± cyclophosphamide. Proc ASCO 1983; 2: 152
   Google Scholar
• Vogl S E, Pagano M, Kaplan B H, Greenwald E, Arsenau J, Bennet B. Cisplatinum based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens. Cancer 1983; 5: 2024–7
   Google Scholar
• Redman C, Lawton F, Stuart N, et al. Phase II study of combination of 4′epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer. Cancer Chemother Pharmacol 1989; 23: 51–3
   PubMed Web of Science ®Google Scholar
• Sugarbaker P H, Cunliffe W J, Graves T, et al. Phase I and pharmacologic studies with early postoperative intraperitoneal (EPI) adriamycin (Adr). Proc AACR 1989; 30: 248
   Google Scholar
• Kolaric K, Potrebica V, Cervek J. Phase-II clinical trial of 4′-epi-doxorubicin in metastatic solid tumours. J Cancer Res Clin Oncol 1983; 106: 148–52
   Google Scholar
• Scarffe J H, Kenny J B, Johnson R J, et al. Phase II trial of epirubicin in gastric cancer. Cancer Treat Rep 1985; 69: 1275–7
   Google Scholar
• Cazap E, Estevez R, Bruno M, et al. Phase II trial of 4′-epi-doxorubicin in locally advanced or metastatic gastric cancer. Tumori 1988; 74: 313–5
   Google Scholar
• Valleios C, Payet C, Nunez J, et al. Combined chemotherapy with FEM protocol for advanced gastric carcinoma. Proc. ECCO-4. Madrid 1987; 38
   Google Scholar
• Flechtner H, Queisser W, Heim M E, et al. 5-fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the ‘Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)’. Onkologie 1987; 10: 67–71
   Google Scholar
• Roth A, Zupanc D, Kolaric K. Open phase II study with combination of 5-fluorouracil, 4-epidoxorubicin and mitomycin C (FEM) in previously untreated patients with metastatic gastric cancer. Proc. 6th NCI EORTC Symposium, Amsterdam, 1989
   Google Scholar
• Kolaric K, Potrebica V, Stanovnik M. Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. Oncology 1986; 43: 73–7
   Google Scholar
• Ferrazzi E, Pappagallo G L, Nicoletto O, et al. Phase II evaluation of 4′epi-doxorubicin in patients with metastatic colorectal carcinoma. Tumori 1984; 70: 297–300
   PubMed Web of Science ®Google Scholar
• Holdener E E, Hansen H H, Høst H, et al. Epirubicin in colorectal cancer. Invest New Drugs 1985; 3: 63–6
   PubMed Web of Science ®Google Scholar
• Moreno Nogueira J A, Murillo E, Duque A, et al. Epirubicin in rectal cancer. Chemiotherapia 1988; 7: 189–94
   Google Scholar
• Maroun J A, Cripps C, Vera S, Gupta S. Phase II study of high dose epirubicin (E) in advanced colorectal carcinoma. Proc ASCO 1989; 8: 112
   Google Scholar
• Vorobiof D A, Falkson G. Phase II study of high-dose 4′epi-doxorubicin in the treatment of advanced gastrointestinal cancer. Eur J Cancer Clin Oncol 1989; 25: 563–4
   PubMedGoogle Scholar
• Blum R H, Lafleur F L, Green M D. and the Adria Study Group. A phase III randomized trial of epirubicin (EPI) vs 5-fluorouracil (5FU) in metastatic rectal/sigmoid adenocarcinoma. Proc. ASCO 1987; 6: 78
   Google Scholar
• Green M C. Phase II trials of the single agents baker's antifol, diaziquone, and epirubicin in advanced pancreatic cancer. Cancer Treat Rep 1987; 71: 865–7
   Google Scholar
• Wils J, Bleiberg H, Blijham G, et al. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1985; 21: 191–4
   PubMedGoogle Scholar
• Wils J, Bleiberg H, Dalesio O, et al. An EORTC gastrointestinal group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1987; 23: 1017–8
   PubMedGoogle Scholar
• Hochster H S, Green M C, Speyer J, et al. 4′epidoxorubicin (epirubicin): Activity in hepatocellular carcinoma. J Clin Oncol 1985; 3: 1535–40
   PubMed Web of Science ®Google Scholar
• Shiu W, Leung N, Li M, Leung W T, Li A K. The efficacy of high-dose 4′epidoxorubicin in hepatocellular carcinoma. J Clin Oncol 1988; 6: 235–7
   Google Scholar
• Epirubicin Study Group for Hepatocellular Carcinoma. Intra-arterial administration of epirubicin in the treatment of nonresectable hepatocellular carcinoma. Cancer Chemother Pharmocol 1987; 19: 183–9
   Google Scholar
• Burkes R, Shephard F, Blackstein M, Goss P, Lassus M. Hepatic arterial infusion (HAI) of 4′epirubicin (EPI) in the treatment of primary hepatocellular carcinoma (HCC). Proc. ASCO 1988; 7: 104
   Google Scholar
• Bonfante V, Villani F, Bonadonna G. Toxic and therapeutic activity of 4-epi-doxorubicin. Tumori 1982; 68: 105–11
   PubMed Web of Science ®Google Scholar
• Ferrazi E, Nicoletto O, Vinante O, et al. Preliminar clinical experience with 4-epi-doxorubicin (epi-DXR). (Abstract 832) 13th UICC International Cancer Congress. Seattle 8—15.9.1982
   Google Scholar
• Hurteloup P, Cappelaere P, Armand J R, Mathé G. Phase II clinical evaluation of 4-epi-doxorubicin. Cancer Treat Rep 1983; 67: 337–41
   PubMedGoogle Scholar
• Robustelli Della Cuna G, Pavesi L, Preti M. Clinical evaluation of 4-epi-doxorubicin in advanced solid tumors. Invest New Drugs 1983; 1: 349–53
   Google Scholar
• Campora E, Nobile M T, Sertoli M R, Rossa R. Phase II study of 4-epi-doxorubicin in advanced breast cancer. Cancer Treat Rep 1984; 68: 1285–6
   Google Scholar
• Rozencweig M, Huinink W TB, Cavalli E, et al. A randomized phase II trial of carminomycin versus 4-epidoxorubicin in advanced breast cancer. J Clin Oncol 1984; 2: 275–81
   Google Scholar
• Gadeberg C C. Treatment with 4′epirubicin in low doses (In Danish.) (Abstract). Farmorubicin Weekly Symposium, Stockholm, 22.9.1985
   Google Scholar
• Jakobsson M, Hakala T, Husa L. A weekly schedule of low dose 4-epidoxorubicin in the treatment of advanced breast cancer. (Abstract). Farmorubicin Weekly Symposium, Stockholm, 1985
   Google Scholar
• Beex L, Speth P, Hoesel Q V, et al. Weekly low dose 4′epi-adriamycin as second line chemotherapy in postmenopausal patients with advanced breast cancer. Proc. ECCO-4. Madrid 1987; 150
   Google Scholar
• Beretta G, Locatelli G, Tabiadon D, Labianca R, Fraschini P, Luporini G. Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen. Oncology 1987; 44: 6–12
   PubMedGoogle Scholar
• Scheulen M E, Niederle N, Schmidt C G. Weekly low-dose epirubicin treatment of metastatic breast cancer. Proc AACR 1987; 28: 197
   Google Scholar
• Tucci E, Algeri R, Guarnieri A, et al. Weekly epirubicin in advanced breast cancer. Tumori 1988; 74: 689–92
   PubMedGoogle Scholar
• Twelwes G J, O'Reilly S O, Coleman R E, et al. Weekly epirubicin for liver metastases in breast cancer. Proc ASCO 1989; 8: 32
   Google Scholar
• Barni S, Tancini G, Paolorossi F, Crispino S, Lissoni P. A weekly schedule of epirubicin in pretreated metastatic breast cancer. Proc ASCO 1989; 8: 29
   Google Scholar
• Jones W G. Effective palliation of advanced breast cancer with weekly low dose epirubicin. Eur J Cancer Clin Oncol 1989; 25: 357–60
   PubMedGoogle Scholar
• Taguchi T, Ogawa M, Izuo M, et al. A prospective randomized trial comparing epirubicin and doxorubicin in advanced or recurrent breast cancer. Gan To Kagaku Ryoho 1986; 13: 3498–507
   Google Scholar
• Van Oosterom A, Andersson M, Wildiers J, et al. Adriamycin (A) versus 4 epi Adriamycin (E). Report of a second-line randomized phase III study in advanced breast cancer. (Abstract 1.6) Proc. IV EORTC Breast Cancer Working Conference, London, 30.6–3.7.1987
   Google Scholar
• Hortobagyi G N, Yap H-Y., Kau S W, et al. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 1989; 12: 57–62
   PubMedGoogle Scholar
• Heidemann E. Factors in the choice of treatment in metastatic breast cancer. Proc ECCO-5. London 1989; 1018
   Google Scholar
• Hardy J R, Powles T J, Coombes R C, Ashley S. A double-blind randomised trial of epirubicin compared with doxorubicin in combination with vincristine and cyclophosphamide for the treatment of advanced breast cancer. Pharmorubicin Update Symposium, London, 1989, 12
   Google Scholar
• Bailey N, Blackledge G, Chetiyawardana A, et al. A controlled randomised study of cyclophosphamide and methotrexate together with either doxorubicin, epirubicin or mitoxantrone in advanced breast cancer. Proc ECCO-5. London 1989; 0973
   Google Scholar
• Romero Acuna L, Galvez C, Blajman C, Morera F, Ruffino C. Chemohormone therapy with Adriamycin or 4′-epi-adriamycin combinations in advanced breast cancer (abc). Previously untreated patients (P). Proc. ECCO-5. Madrid 1989; 1027
   Google Scholar
• Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. New Engl J Med 1981; 304: 10–5
   PubMed Web of Science ®Google Scholar
• Brufman G, Sulkes A, Fuks Z, Biran S. Cytoxan, methotrexate and 5-fluorouracil (CMF) chemotheraphy in metastatic breast cancer: The influence of dose levels and performance status upon response rates and survival. Proc ASCO, C-402: 103
   Google Scholar
• Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 1985; 45: 4454–9
   PubMed Web of Science ®Google Scholar
• Korzun A, Norton L, Perloff M, et al. Clinical equivalence despite dosage differences of two schedules of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) for adjuvant therapy of node-positive stage II breast cancer. Proc ASCO 1988; 7: 12
   Google Scholar
• Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–8
   PubMed Web of Science ®Google Scholar
• Cooper R G, Holland J F, Glidewell O. Adjuvant chemotherapy of breast cancer. Cancer 1979; 44: 793–8
   PubMed Web of Science ®Google Scholar
• Henderson I C, Hayes D F, Gelman R. Dose-response in the treatment of breast cancer: A critical review. J Clin Oncol 1988; 6: 1501–15
   PubMed Web of Science ®Google Scholar
• Gelman R S, Henderson I C. A reanalysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. SAKK Bull 1987; 1: 10–2
   Google Scholar
• Tannock I F, Boyd N F, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377–87
   PubMed Web of Science ®Google Scholar
• Beretta G, Tabiadon D, Tedeschi L, Cambrosier P, Beretta G D, Luporini G. Front line treatment with CMF variations for advanced breast carcinoma. A randomized study. Proc ASCO 1986; 77
   Google Scholar
• Creech R H, Catalano R B, Hopson R C. A comparison of standard-dose adriamycin and low-dose Adriamycin as primary chemotherapy for metastatic breast cancer. Proc AACR 1980; 566: 142
   Google Scholar
• Carmo-Pereira J, Oliveira Costa F, Henriques E, et al. A comparison of two doses of Adriamcyin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 1987; 56: 471–3
   PubMed Web of Science ®Google Scholar
• Ebbs S R, Graham H, A'Hern R P, Bates T, Baum M. A prospective randomized trial comparing low and high dose epirubicin given as either bolus injection or prolonged infusion for advanced breast cancer. Proc 3rd Scand Breast Cancer Symposium, Örenäs, 1988, 13
   Google Scholar
• Becher R, Kurschel E, Kleke O, et al. Randomized study of epirubicin and cyclophosphamide in advanced breast cancer. Proc ASCO 1988; 125: 32
   Google Scholar
• Hortobagyi G, Bodey G P, Buzdar A U, et al. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study. J Clin Oncol 1987; 5: 354–64
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Triallists Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on the mortality in early breast cancer. New Engl J Med 1988; 319: 1681–92
   Google Scholar
• Brincker H. Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen. Acta Oncol 1988; 27: 729–32
   Google Scholar
• Fisher B, Redmond C, Wickerham L, et al. Doxorubicin-containing regimens for the treatment of stage II breast Cancer: The rational surgical adjuvant breast and bowel project experience. J Clin Oncol 1989; 7: 572–82
   PubMed Web of Science ®Google Scholar
• Coombes R C, Chilvers C, Palmer A, et al. Adjuvant 4-epirubicin, 5-fluorouracil and cyclophosphamide (FEC) in node positive premenopausal breast cancer patients. Proc Symp Epirubicin: Present status and future development. ECCO-4. Madrid Nov 3, 1987
   Google Scholar
• Jones S E, Mennel R G, Peters G N, et al. Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer. Invest New Drugs 1988; 6: 195–8
   Google Scholar